Breaking Down Silk Road Medical: 5 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Silk Road Medical (NASDAQ:SILK) has been analyzed by 5 analysts, showing a shift towards a more bullish outlook with 3 bullish and 2 neutral ratings recently. The average 12-month price target is now $20.00, up 60% from the previous $12.50, with a high estimate of $23.00 and a low of $18.00. The company, focusing on reducing stroke risk through its TCAR procedure, shows positive revenue growth and a strong net margin but below-average ROE and ROA. Its market capitalization is below the industry average, indicating a smaller scale compared to peers.
February 29, 2024 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silk Road Medical has seen a positive shift in analyst sentiment, with an increased average price target reflecting a bullish outlook. The company's innovative approach to stroke prevention and strong financial performance indicators like revenue growth and net margin are likely to bolster investor confidence.
The shift towards a more bullish outlook by analysts, coupled with the company's positive revenue growth and strong net margin, suggests a potential increase in investor confidence and stock price. The upward revision of the 12-month price target to $20.00, representing a 60% increase, further supports the likelihood of a positive short-term impact on SILK's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100